[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100622345":3},{"organization":4,"armGroups":7,"interventions":28,"overallOfficials":23,"centralContacts":38,"locations":45,"responsibleParty":57,"collaborators":61,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":67,"sex":73,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":23,"studyType":79,"phases":80,"briefSummary":82,"conditions":83,"keywords":23,"overallStatus":88,"whyStopped":23,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Herlev and Gentofte Hospital","OTHER",[8,14,19,24],{"label":9,"type":10,"description":11,"interventionNames":12},"LDL letter only","EXPERIMENTAL","Participants randomized to the LDL-C letter but not the Lp(a) letter",[13],"Behavioral: LDL-C information letter",{"label":15,"type":10,"description":16,"interventionNames":17},"Lp(a) letter only","Participants randomized to the Lp(a) letter but not the LDL-C letter.",[18],"Behavioral: Lp(a) information letter",{"label":20,"type":21,"description":22,"interventionNames":23},"No letter","NO_INTERVENTION","Participants randomized to no LDL-C letter and to no Lp(a) letter",null,{"label":25,"type":10,"description":26,"interventionNames":27},"LDL-C and Lp(a) letter","Participants randomized to the LDL-C letter and the Lp(a) letter",[13,18],[29,34],{"type":30,"name":31,"description":32,"armGroupLabels":33,"otherNames":23},"BEHAVIORAL","LDL-C information letter","An electronically delivered informational letter communicating the participant's elevated LDL-C level and its relevance to ASCVD, with encouragement to consult their physician if relevant. Delivered via the Danish Digital Post system.",[9,25],{"type":30,"name":35,"description":36,"armGroupLabels":37,"otherNames":23},"Lp(a) information letter","An electronically delivered informational letter describing elevated Lp(a) as a genetically determined cardiovascular risk factor, with encouragement to discuss risk factor optimization with a physician if relevant.",[25,15],[39],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Tor Biering-Sørensen, MD, MPH, MSc, PhD","CONTACT","28933590","+45","tor.biering-soerensen@regionh.dk",[46],{"facility":47,"status":23,"city":48,"state":49,"zip":50,"country":51,"countryCode":52,"cosmosGeoPoint":23,"geoPoint":23,"contacts":53},"Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte, Hellerup, 2900","Hellerup","Region Sjælland","2900","Denmark","DK",[54],{"name":55,"role":41,"phone":56,"phoneExt":23,"email":44},"Tor Biering-Sørensen, MD, MSc, MPH, PhD","+4528933590",{"type":58,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"SPONSOR_INVESTIGATOR","Tor Biering-Sørensen","Professor, MD, MSc, MPH, PhD",[62],{"name":63,"class":64},"Novartis","INDUSTRY","100622345","electronic-letters-to-improve-patient-activation-in-ihd-the-nudge-ihd-trial-100622345",false,"NCT07382414","Electronic Letters to Improve Patient Activation in IHD: The NUDGE-IHD Trial","NUDGE-IHD: A Nationwide Pragmatic Randomized Trial of Electronic Nudges to Increase Patient Activation to Support Risk-factor Control in Ischemic Heart Disease","NUDGE-IHD","Inclusion criteria\n\n* Alive on identification date\n* Diagnosis of IHD defined as either an A or B diagnosis code of I20-I25 in the Danish National Patient Register first registered \\> 6 months prior to identification date\n* Latest available LDL-C is over 1.4 mmol\u002Fl measured up to 3 years prior to the identification date, defined using NPU codes NPU01568, NPU10171 or DNK35308 from the Danish National Laboratory Register\n* Age \\>= 18 years and \\\u003C= 85 on identification date\n\nExclusion criteria\n\n* Nursing home residents\n* Exemption from and thus not access to Digital Post","ALL","18 Years","85 Years",{"count":77,"type":78},100000,"ESTIMATED","INTERVENTIONAL",[81],"NA","The goal of this clinical trial is to learn whether simple electronic information letters can increase patient activation and improve risk-factor monitoring in adults in Denmark with ischemic heart disease (IHD) who have LDL cholesterol above the recommended treatment target. A subgroup of participants with elevated lipoprotein(a) \\[Lp(a)\\] will also be randomized to receive an additional information letter.\n\nThe main questions the study aims to answer are:\n\n* Does sending an electronic letter about elevated LDL cholesterol increase the proportion of patients who have at least one LDL-cholesterol test within 6 months?\n* Among patients with ischemic heart disease and elevated Lp(a), does receiving an information letter about Lp(a) increase patient activation, reflected by cardiometabolic risk-factor monitoring?\n\nBecause this is a randomized trial, researchers will compare people who receive the electronic letter(s) with people who do not receive any letter to determine whether the letters encourage patients to take action, such as obtaining laboratory tests or contacting their doctor.\n\nParticipants will:\n\n* Receive an electronic letter through Denmark's national digital mailbox system (Digital Post) or receive no letter, depending on random assignment.\n* Continue their usual health care, with no additional visits, treatments, or procedures required for the study.\n* Have all study information collected from existing Danish nationwide health registries.",[84,85,86,87],"Coronary Artery Disease","Hypercholesterolemia","Lipoprotein(a)","Secondary Prevention","NOT_YET_RECRUITING","2026-03-08",{"date":91,"type":92},"2026-03-10","ACTUAL",{"date":94,"type":78},"2026-04",{"date":96,"type":78},"2026-10",{"name":59,"class":6},1]